2026 Hereditary Cancer Genetics: Incorporation into Clinical Care

Thursday, September 17, 2026, 10:00 AM - Friday, September 18, 2026, 5:30 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY

This two-day conference provides comprehensive professional training in clinical cancer genetics, hosted by Memorial Sloan Kettering Cancer Center (MSK) — one of the nation’s largest cancer genetics centers. The program features expert faculty with specialized expertise in disease-specific management and offers opportunities for participants to engage directly with speakers through panel discussions and case-based presentations. The course is designed to establish a strong foundation in cancer genetics, examine the clinical implications of genetic testing for patient care, and highlight emerging advances in cancer genomics.

Program Highlights

• Current topics in hereditary breast, gynecologic, gastrointestinal, genitourinary, and pediatric cancers

• Hereditary hematologic malignancies and rare cancer syndromes

• Surveillance strategies and precision oncology

• Advances and research in diagnosis, early detection, and cancer prevention strategies

• Multidisciplinary panel discussions and case studies

• Networking opportunities, including a reception on Friday evening 

Keynote Speakers

	Niehaus, Southworth, Weissenbach Award Lecture Professor Ros Eeles, FMedSci, PhD, FRCP, FRCR The Institute of Cancer Research London, UK
	Niehaus Visiting Professor Lecture Sharon A. Savage, MD National Cancer Institute National Institutes of Health Bethesda, MD, USA

Target Audience: This course is intended for medical oncologists, genetic counselors, advanced practice providers, nurses, and other healthcare professionals seeking to incorporate cancer genetic testing into patient care. Participants may attend in person or virtually.

Syllabus: Following the conference, participants will receive access to an online syllabus with recorded presentations and downloadable slide PDFs.

1. Identify clinical features of hereditary cancer predisposition syndromes and facilitate interpretation of genetic test results
2. Evaluate the recommended surveillance and risk reduction interventions for patients with hereditary cancer predisposition syndromes
3. Enhance awareness of implications of germline genetic testing on therapeutic management of patients with cancer, including oncological and surgical interventions
4. Apply concepts of germline variant analysis and tumor profiling to enhance clinical care of patients at risk for hereditary cancer syndromes
5. Discuss novel advances and technologies to help improve the early detection of hereditary cancers

Registration Fees (In-Person or Virtual)

• Physicians (MDs, PhDs, DOs): $300

• Advanced Practice Providers: $200

• Residents, Fellows, Nurses, and Other Healthcare Professionals: $150

• Industry Professionals: $525*

• MSK Employees: Complimentary**

Registration Discounts: Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information.

Cancellation Policy: For details on our cancellation terms, please review our Cancellation Policy.

*An industry professional is defined as any individual, irrespective of their provider type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company. Please review our Registration Policy for Industry Professionals for more information.
**MSK employees receive complimentary registration for all CME programs by signing in with MSK credentials (SSO).

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™, ABIM MOC, ABS CC available. ANCC CNE contact hours and Category 1 CEUs for Genetic Counselors pending.

We look forward to welcoming you to Memorial Sloan Kettering Cancer Center (MSK). If you will be traveling to New York City from out of town, we encourage you to arrange your accommodations as early as possible.

Hotel Accommodations: To assist with your planning, MSK has arranged preferred rates and amenities at select hotels in Manhattan. Click here to view participating hotels and additional details.

Travel and Parking:  For information on traveling to MSK, including directions and parking options, click here. Please note that parking validation is not available for conference attendees.

If you require any specific accommodations to attend this event in person, please contact [email protected] at least one week in advance.

 

MSK Conference Directors

Kelsey Breen, MS, MSc, CGC
Lead Genetic Counselor, Clinical Genetics Service
Department of Medicine 

Kenneth Offit, MD, MPH
Niehaus Center Director
Chief, Clinical Genetics Service
Robert and Kate Niehaus Chair in Inherited Cancer Genomics
Vice Chair, Academic Affairs, Department of Medicine
Co-Leader, Population Sciences Research
Department of Medicine

Alicia Latham, MD, MS
Medical Director, MSK-CATCH Lead, Rare Cancer Syndrome Genetics and Cancer Interception, Niehaus Center
Assistant Attending, General Internal Medicine and Clinical Genetics Services
Department of Medicine

Zsofia K. Stadler, MD
Clinical Director, Clinical Genetics Service
Associate Director, Robert and Kate Niehaus Center for Inherited Cancer Genomics
Attending, Gastrointestinal Oncology Service 
Department of Medicine

Keynote Speakers

Niehaus, Southworth, Weissenbach Award Lecture
Professor Ros Eeles, FMedSci, PhD, FRCP, FRCR
Professor of Oncogenetics
Group Leader, Oncogenetics Team
The Institute of Cancer Research
Honorary Consultant in Clinical Oncology and Cancer Genetics
The Royal Marsden NHS Foundation Trust
London, UK

Niehaus Visiting Professor Lecture
Sharon A. Savage, MD
Director, Clinical Genetics Branch
Clinical Director, Division of Cancer Epidemiology and Genetics
National Cancer Institute
National Institutes of Health
Bethesda, MD, USA

 

A complete faculty list will be available soon. 

 

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.